Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has earned an average rating of “Hold” from the seven brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $5.89.

A number of analysts recently issued reports on ANTH shares. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $1.75 price target (down from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th.

A number of institutional investors and hedge funds have recently bought and sold shares of ANTH. Wedbush Securities Inc. lifted its holdings in Anthera Pharmaceuticals by 75.8% during the third quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 31,800 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Anthera Pharmaceuticals by 1,376.1% during the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 335,595 shares in the last quarter. Finally, UBS Group AG lifted its holdings in Anthera Pharmaceuticals by 9.9% during the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 33,901 shares in the last quarter. 26.10% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/13/anthera-pharmaceuticals-inc-anth-receives-average-rating-of-hold-from-analysts.html.

Shares of Anthera Pharmaceuticals (NASDAQ ANTH) remained flat at $$1.86 during midday trading on Monday. The company’s stock had a trading volume of 1,851,200 shares, compared to its average volume of 330,276. Anthera Pharmaceuticals has a 52-week low of $1.20 and a 52-week high of $20.24.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.32. During the same quarter in the previous year, the company earned ($4.85) EPS. analysts anticipate that Anthera Pharmaceuticals will post -3.34 EPS for the current fiscal year.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.